TP53 and prostate carcinoma: Moreover, in prostate cancer cells, inactivation of both ELL-associated factor 2 (EAF2) and p53 can enhance STAT3 phosphorylation and drive tumorigenesis, and this regulation of STAT3 phosphorylation by EAF2 and/or p53 may involve multiple mechanisms [104].